Related Experiment Video
Updated: Nov 18, 2025

Studying RNA Interactors of Protein Kinase RNA-Activated during the Mammalian Cell Cycle
Published on: March 5, 2019
PRKAA/AMPKα phosphorylation switches the role of RASAL2 from a suppressor to an activator of autophagy
Yong Bao1,2, Christopher Qian3, Meng-Yue Liu1
1Institute of Translational and Precision Medicine, Nantong University, Nantong, China.
Abstract:
RASAL2 (RAS protein activator like 2), a RASGTPase activating protein, can catalyze the hydrolysis of RAS-GTP into RAS-GDP to inactivate the RAS pathway in various types of cancer cells. However, the cellular function of RASAL2 remains elusive. Here we showed that RASAL2 can attenuate PRKAA/AMPKα phosphorylation by recruiting phosphatase PPM1B/pp2cβ, thus inhibiting the initiation of basal autophagy under normal conditions. In addition, we found that glucose starvation could induce dissociation of PPM1B from RASAL2 and then RASAL2 at S351 be phosphorylated by PRKAA, followed by the binding of phosphorylated-RASAL2 with to PIK3C3/VPS34-ATG14-BECN1/Beclin1 complex to increase PIK3C3 activity and autophagy. Furthermore, RASAL2 S351 phosphorylation facilitated breast tumor growth and correlated to poor clinical outcomes in breast cancer patients. Our study demonstrated that the phosphorylation status of RASAL2 S351 can function as a molecular switch to either suppress or promote AMPK-mediated autophagy. Inhibition of RASAL2 S351 phosphorylation might be a potential therapeutic strategy to overcome the resistance of AMPK-activation agents.Abbreviations: AICAR: aminoimidazole carboxamide ribonucleotide; AMPK: adenosine 5'-monophosphate (AMP)-activated protein kinase; ATG14: autophagy related 14; C.C: compound C; CQ: chloroquine; DKO: double-knockout; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MTOR: mechanistic target of rapamycin kinase; PIK3C3/VPS34: phosphatidylinositol 3-kinase catalytic subunit type 3; PIK3R4/VPS15: phosphoinositide-3-kinase regulatory subunit 4; PPM1B/pp2cβ: protein phosphatase, Mg2+/Mn2+ dependent 1B; PRKAA/AMPKα: protein kinase AMP-activated catalytic subunit alpha; PtdIns: phosphatidylinositol; PtdIns3P: phosphatidylinositol-3-phosphate; RASAL2: RAS protein activator like 2; RasGAPs: RasGTPase activating proteins; SQSTM1/p62: sequestosome 1; TNBC: triple-negative breast cancer.
Insights
RASAL2 regulates autophagy by controlling AMPK phosphorylation. Its S351 phosphorylation promotes breast tumor growth, suggesting therapeutic targeting for cancer treatment.
Area of Science:
- Molecular Biology
- Cellular Biology
- Cancer Research
Background:
- RASAL2 (RAS protein activator like 2) is a RAS GTPase activating protein that inactivates the RAS pathway in cancer.
- The precise cellular functions of RASAL2 are not fully understood.
- Autophagy, a cellular degradation process, plays a complex role in cancer development and progression.
Purpose of the Study:
- To elucidate the role of RASAL2 in regulating autophagy.
- To investigate the mechanism by which RASAL2 influences autophagy initiation and promotion.
- To determine the clinical significance of RASAL2 phosphorylation in breast cancer.
Main Methods:
- Investigated RASAL2's interaction with protein phosphatase PPM1B/pp2cβ.
- Examined the effect of glucose starvation on RASAL2 and PRKAA/AMPKα.
- Analyzed the phosphorylation status of RASAL2 at S351 and its impact on the PIK3C3/VPS34 complex.
- Correlated RASAL2 S351 phosphorylation with clinical outcomes in breast cancer patients.
Main Results:
- RASAL2 inhibits basal autophagy under normal conditions by recruiting PPM1B/pp2cβ to attenuate PRKAA/AMPKα phosphorylation.
- Glucose starvation triggers dissociation of PPM1B/pp2cβ from RASAL2, leading to PRKAA/AMPKα-mediated phosphorylation of RASAL2 at S351.
- Phosphorylated RASAL2 enhances PIK3C3/VPS34 activity and promotes autophagy.
- RASAL2 S351 phosphorylation is linked to increased breast tumor growth and poorer clinical outcomes in breast cancer patients.
Conclusions:
- RASAL2 acts as a molecular switch controlling AMPK-mediated autophagy through its S351 phosphorylation status.
- RASAL2 phosphorylation can either suppress or promote autophagy, influencing cancer progression.
- Targeting RASAL2 S351 phosphorylation may offer a therapeutic strategy to overcome resistance to AMPK-activation agents in cancer therapy.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
MAPK Signaling Cascades
The Ras Gene
Ras is a...
The JAK-STAT Signaling Pathway
cAMP-dependent Protein Kinase Pathways

